The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

358

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

March 19, 2024

Study Completion Date

March 19, 2024

Conditions
LaparoscopyAnesthesia, Intravenous
Interventions
DRUG

BT-KTM-I

The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.

DRUG

Ketanest®S

The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.

Trial Locations (12)

Unknown

The First Affiliated Hospital of Jinan University, Guangzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

Guizhou Provincial People's Hospital, Guiyang

The Affiliated Hospital of Guizhou Medical University, Guiyang

Hunan Provincial Maternal and Child Health Care Hospital, Changsha

The Third Xiangya Hospital of Central South University, Changsha

The Second Hospital University of South China, Hengyang

Pidu District People's Hospital, Chengdu, Chengdu

Sichuan Provincial People's Hospital, Chengdu

West China Second University Hospital, Sichuan University, Chengdu

The Second People's hospital of Neijiang, Neijiang

The Second People's Hospital of Yibin, Yibin

All Listed Sponsors
lead

Chengdu Brilliant Pharmaceutical Co., Ltd.

INDUSTRY

NCT06092684 - The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery | Biotech Hunter | Biotech Hunter